Company Encyclopedia
View More
name
VYNE Therapeutics
VYNE.US
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc.
4.361 T
VYNE.USMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking100/182
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-70.67%E
    • Profit Margin-6425.19%E
    • Gross Margin100.00%A
  • Growth ScoreC
    • Revenue YoY6.29%C
    • Net Profit YoY1.41%C
    • Total Assets YoY-52.58%E
    • Net Assets YoY-49.50%E
  • Cash ScoreC
    • Cash Flow Margin-1.56%D
    • OCF YoY6.29%C
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio11.19%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Vyne Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting

    Vyne Therapeutics Inc. will hold its Annual Meeting of Stockholders on December 12, 2025, in Bedminster, New Jersey. Shareholders will vote on the election of two Class I directors to serve until the 2028 annual meeting and the ratification of Baker Tilly US, LLP as the company’s independent registered public accounting firm.

    Reuters·
    US
    VYNE
    -3.30%
    Reuters·
    US
    VYNE
    -3.30%

    VYNE Therapeutics (VYNE) Gets a Buy from TD Cowen

    TD Cowen analyst Stacy Ku has maintained a Buy rating on VYNE Therapeutics, setting a price target of $2.00. Ku, who focuses on the Healthcare sector, has an average return of 13.1% and a 60.34% success rate on recommended stocks. The current analyst consensus on VYNE Therapeutics is a Moderate Buy, with an average price target also at $2.00.

    Tip Ranks·
    US
    VYNE
    -3.30%
    Tip Ranks·
    US
    VYNE
    -3.30%

    Foghorn Therapeutics Reports Q3 2025 Financial Results

    Foghorn Therapeutics, Inc. (FHTX) reported its Q3 2025 financial results, showing a net loss of $15.8 million, an improvement from $19.1 million last year. The company generated $8.2 million in collaboration revenue, mainly from its partnership with Eli Lilly. Operating expenses decreased to $26.7 million, driven by lower research and development costs. Cash and cash equivalents rose to $89.3 million, with total assets at $205 million. Foghorn plans to continue investing in R&D while pursuing long-term growth despite expected ongoing losses.

    Tip Ranks·
    US
    FHTX
    -5.56%
    Tip Ranks·
    US
    FHTX
    -5.56%

    VYNE Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 169 K

    LB filings·
    US
    VYNE
    -3.30%
    LB filings·
    US
    VYNE
    -3.30%

    VYNE Therapeutics Q3 net loss narrows, strategic review ongoing

    VYNE Therapeutics reported a narrowed Q3 net loss of $7.28 million, with revenue of $169,000. The company is undergoing a strategic review to explore partnerships or mergers, aiming to maximize shareholder value. Cost reductions have been implemented to extend the cash runway into the first half of 2027. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $3.25, significantly above its recent closing price of $0.34.

    Reuters·
    US
    VYNE
    -3.30%
    Reuters·
    US
    VYNE
    -3.30%